Share This Page
Drugs in ATC Class J05AJ
✉ Email this page to a colleague
Drugs in ATC Class: J05AJ - Integrase inhibitors
| Tradename | Generic Name |
|---|---|
| DUTREBIS | lamivudine; raltegravir potassium |
| ISENTRESS | raltegravir potassium |
| ISENTRESS HD | raltegravir potassium |
| RALTEGRAVIR POTASSIUM | raltegravir potassium |
| GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate |
| >Tradename | >Generic Name |
Integrase inhibitors patent landscape in ATC Class J05AJ: market dynamics, exclusivity timelines, and key IP barriers
ATC Class J05AJ (integrase inhibitors) is dominated by dolutegravir-based regimens, with bictegravir and cabotegravir as the main growth drivers. Patent coverage is split across (1) drug substance and key intermediates, (2) formulation and fixed-dose combination patents, (3) method-of-treatment claims, and (4) manufacturing/process claims. Near-term market dynamics are shaped by staggered first approval dates, multiple Orange Book listing layers per NDA (especially for fixed-dose combinations), and repeat-challenge strategies that target specific strengths and dosage forms.
Key business takeaway: most “generic entry risk” is not single-patent elimination but dossier timing plus the ability to design around a dense set of late-life formulation and method-of-use claims tied to common HIV regimens.
Which integrase inhibitors are in ATC J05AJ and how do their patent estates differ by mechanism?
Featured snippet answer: J05AJ covers integrase strand transfer inhibitors (INSTIs) including dolutegravir, bictegravir, and cabotegravir (including long-acting cabotegravir formulations), plus associated combination products.
ATC J05AJ agents and key competitive positioning
- Dolutegravir (DTG): anchor INSTI in first-line therapy and key component of multiple fixed-dose combinations (FDCs).
- Bictegravir (BIC): typically in single-tablet regimens; strong differentiation via once-daily profiles and multi-NDA coverage via FDC patents.
- Cabotegravir (CAB): short-acting oral products plus long-acting injectable cabotegravir used with long-acting rilpivirine for maintenance and prevention-associated programs in specific settings.
Patent estate shape: what to expect
- Dolutegravir: long runway due to early filing and multiple filing families, then “triple-layer” closing: FDC patents, low-level process patents, and late-manufacturing/particle-size/formulation improvements.
- Bictegravir: similarly dense, but often concentrated around FDC and method-of-use claims aligned to widely adopted regimens.
- Cabotegravir: estate includes additional layers tied to injectable formulation, depot technology, and stability/manufacturing process claims that are harder to design around than simple tablet formulations.
What patents protect dolutegravir, bictegravir, and cabotegravir in the US and Europe?
Featured snippet answer: Protection typically spans (1) integrase inhibitors as compounds, (2) key intermediates and stereochemical series, (3) salt forms (where applicable), (4) FDC composition claims, and (5) manufacturing and formulation patents specific to dosage forms.
Typical US IP coverage mapped to claim layers
For each INSTI, US coverage usually clusters into:
- Composition of matter (drug substance)
- Pharmaceutical composition (formulation)
- Method-of-treatment (often for HIV-1 infection and regimen constructs)
- Process/manufacturing claims
- Device or delivery claims (more relevant to CAB LA injectables)
Typical Europe (EP) portfolio structure
- EP filings often include parallel claim sets for:
- active ingredient and salts/polymorphs,
- pharmaceutical compositions,
- combinations with NRTIs/NNRTIs,
- manufacturing methods.
How long does patent exclusivity last for J05AJ integrase inhibitors in the US?
Featured snippet answer: Effective exclusivity depends on the patent expiration schedule, the Orange Book–listed patent grant and expiry, and regulatory exclusivities (RDP/NCE/30-month stay dynamics and any pediatric extensions). In practice, late-life formulation/FDC patents often govern the ability to launch “at scale” even after earlier compound patents expire.
US exclusivity timeline mechanics that matter for market entry
- Orange Book list drives NDA-specific litigation risk through the Hatch-Waxman framework.
- Paragraph IV challenges typically target the last “blocking” Orange Book patents tied to the exact drug product (strength, dosage form, and/or FDC).
- 30-month stay can compress generic launch timelines if the first challenge occurs.
- Manufacturing-process and formulation patents can extend practical exclusivity because they are product-specific.
When does each integrase inhibitor lose exclusivity: what are the practical launch dates?
Featured snippet answer: The practical “exclusivity loss” date for generics is usually the date when the last Orange Book–listed patent relevant to the intended product is no longer enforceable (or has been invalidated/expired via settlement or litigation outcome), not the earliest compound patent expiry.
What “practical loss of exclusivity” tends to look like
- Early years: compound patents dominate.
- Mid-to-late years: formulation and FDC patents dominate.
- Cabotegravir LA: depot injectable formulation and process claims can remain blocking even after oral compound protections narrow.
Market entry scenario framework
- Scenario A: FDC blocker lasts
A generic can enter the single agent but not the widely prescribed FDC until the FDC-specific patents resolve. - Scenario B: strength-specific Orange Book coverage
A sponsor can sometimes sell a non-blocked strength or dosage form if it matches an Orange Book listing strategy. - Scenario C: settlement-driven timing
Many launches follow “carve-outs” tied to country/strength and a delayed entry date.
What patent litigation affects generic entry for integrase inhibitors?
Featured snippet answer: INSTI generic entry is often constrained by (1) frequent Paragraph IV filings against Orange Book patents, (2) settlements that delay launch by product/strength, and (3) injunction threats that force “design-around” strategies.
Common litigation targets in J05AJ
- Method-of-treatment patents tied to first-line or maintenance regimen constructs
- FDC composition patents for co-packaged or fixed-dose regimens
- Formulation patents covering release profiles and excipients
- Process patents for API or formulation manufacturing
How litigation shapes market dynamics
- Settlement outcomes often define:
- earliest allowable launch date,
- exclusivity “carve-out” strengths and dosages,
- permissible label indications and dosing language.
Which companies are challenging integrase inhibitor patents and where do challenges concentrate?
Featured snippet answer: Generic and biosimilar-adjacent competitors typically challenge within the US Orange Book ecosystem where the sponsor has multiple listed patents. For INSTIs, challenges cluster around the most prescribed FDCs and liquid/solid dosage forms.
Challenge concentration patterns
- US-focused challenges follow the biggest-volume NDA products (FDCs with broad guideline adoption).
- Repeat challenges emerge once earlier patents drop, targeting the next blocking patent in the Orange Book list.
- Design-around attempts track claim language: salt, polymorph, excipient, particle size, dissolution profile, and combination composition.
What is the Orange Book status of integrase inhibitor products and how many patents block entry?
Featured snippet answer: Integrase inhibitors commonly have multiple Orange Book listed patents per NDA, and the number of blocking patents can exceed the number of visible “headline” compound patents due to formulation and combination layering.
How to read Orange Book strategically (business use)
- Count Orange Book patents by:
- type (compound vs formulation vs method of use),
- expiration date,
- whether the listing matches the generic target product (strength, dosage form, FDC combination).
Practical implications for entry risk
- A generic filer can clear one listed patent but still face blocking claims covering:
- the precise FDC composition,
- the specific strength manufactured under a blocked process claim,
- method-of-use language.
What formulations are protected for dolutegravir and bictegravir FDCs?
Featured snippet answer: Formulation protection frequently covers fixed-dose combinations and solid oral dosage characteristics, including dissolution behavior, excipient selection, and manufacturing conditions that affect critical quality attributes.
Formulation patent risk drivers in FDCs
- Co-crystal and salt behavior (if claimed)
- Dissolution and release profile
- Particle size/distribution affecting bioavailability
- Stability studies and packaging configurations
- Manufacturing process steps tied to API/formulation performance
What is protected in cabotegravir long-acting injectable technology?
Featured snippet answer: Cabotegravir LA adds injectable depot and manufacturing/process layers that are frequently harder to “work around” than oral tablet formulation patents.
Key technical IP buckets for CAB LA
- Depot formulation (drug in a matrix suitable for sustained release)
- Particle attributes affecting release kinetics
- Sterility and aseptic process controls that tie to manufacturing IP
- Stability and shelf-life claims
- Injection device/administration-related aspects where claimed
How does each integrase inhibitor compare on biosimilar-style risk and biologic-adjacent concerns?
Featured snippet answer: Biosimilar frameworks do not apply to small-molecule INSTIs; the relevant “biologic-like” concern is rather complex manufacturing for LA injectable (CAB) and formulation-design barriers that can function like “complexity” entry hurdles.
Small-molecule vs depot complexity
- Oral INSTIs: typical ANDA path with chemical and formulation comparability expectations.
- CAB LA: higher manufacturing and formulation comparability burden can extend practical entry risk even if patents thin.
What generic entry risks exist for integrase inhibitors when patents expire?
Featured snippet answer: Even after compound patents expire, generic entry risk persists due to late-life:
- formulation and FDC patents,
- method-of-use claims (if aligned to label scope),
- process/manufacturing claims tied to dossier development.
The highest-risk “last-mile” barriers
- FDC-specific patents that block the dominant SKU set.
- Formulation patents tied to dissolution, release, or stability metrics.
- Manufacturing process patents for API or final dosage form.
Which regulatory pathway decisions interact with patent strategy for integrase inhibitors?
Featured snippet answer: ANDA Paragraph IV certification timing drives 30-month stays and settlement leverage; label scope and dosing language are often synchronized with litigation positions.
How regulatory filings play into commercial outcomes
- A generic’s ability to launch is constrained by:
- patent expiry vs injunction risk,
- approved strength/dosage form match,
- product labeling tied to method-of-use constraints.
What licensing deals or settlements typically drive market timing for INSTIs?
Featured snippet answer: Settlements typically delay launch by:
- specifying a launch date,
- limiting sales to non-blocked strengths or formulations,
- restricting label claims and marketing.
Settlement dynamics that matter for business
- First Paragraph IV outcomes often determine:
- whether subsequent challengers file earlier or wait,
- whether the brand escalates additional Orange Book listings or continues litigation against remaining challengers.
Key timelines and milestone map: what to monitor across the J05AJ portfolio?
Featured snippet answer: Track four parallel calendars: Orange Book expiries, pediatric extension status (if any), 30-month stay windows, and settlement-defined carve-out/launch dates.
Monitoring matrix
- Patent: grant/expiration for each Orange Book listed patent tied to the exact dosage form and strength
- Regulatory: NDA approvals for FDC combinations and any supplemental approvals that add Orange Book listings
- Litigation: filing date of Paragraph IV, scheduled Markman dates, and final judgment windows
- Commercial: brand SKU mix (tablet vs LA injectable vs FDC) that determines where blocking patents matter most
Key Takeaways
- J05AJ integrase inhibitor market dynamics are governed less by single compound patent expiry and more by dense Orange Book layering across FDC, formulation, and method-of-use claims.
- Dolutegravir and bictegravir face generic entry pressure once early compound protection narrows, but practical launch is typically delayed by last-mile formulation/FDC patents.
- Cabotegravir introduces additional depot formulation and manufacturing/process barriers for long-acting injectable products, raising product-specific entry risk even where compound patents have weakened.
- For generic and licensing strategy, “blocking patents” are those that match the intended strength, dosage form, and regimen labeling, not the broader active ingredient family.
- Litigation and settlements define launch calendars via 30-month stays and carve-outs that control near-term revenue exposure for incumbents and entry timing for challengers.
FAQs
1) What Orange Book patent types most often block integrase inhibitor generic launches?
Formulation, FDC composition, and method-of-use listings tied to the specific marketed dosage form and strength typically create the last-mile barriers, driving delayed approvals or settlement carve-outs.
2) Can a generic launch an integrase inhibitor single agent while its FDC is still blocked?
Often yes, if the Orange Book blocking listings are product-specific and the generic’s intended NDA/SKU matches an unblocked patent set. Brand settlements commonly restrict this via carve-outs.
3) What makes cabotegravir long-acting injectables harder to replicate than oral INSTIs?
Depot formulation and release kinetics are supported by formulation and manufacturing process IP, which can require more complex design-around work and stronger comparability documentation.
4) Do method-of-use patents materially affect labeling for integrase inhibitor generics?
They can, especially when claim language targets regimen constructs that map onto label indications and dosing language. Settlement terms can also constrain marketing.
5) Are Paragraph IV challenges on integrase inhibitors primarily early-entry tactics or repeat-challenge strategies?
Both. Early challenges target headline blockers; repeat challenges then target later-expiring Orange Book listings that remain enforceable for the exact marketed product.
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Hatch-Waxman Drug Patent Certification and 30-Month Stay (general guidance and framework). U.S. Food and Drug Administration. https://www.fda.gov/
- United States Patent and Trademark Office. Patent term and expiration basics (general). https://www.uspto.gov/
More… ↓
